Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 14 clinical trials
A Study to Evaluate ELX/TEZ/IVA on Cough and Physical Activity in Subjects With Cystic Fibrosis (CF)

This study will evaluate the effects of elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) on cough and physical activity using wearable technology in CF participants.

elexacaftor
fibrosis
ivacaftor
tezacaftor
forced expiratory volume
  • 0 views
  • 17 Mar, 2022
  • 16 locations
A Phase 3 Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Heterozygous for F508del and a Minimal Function Mutation (F/MF)

The purpose of this study is to evaluate the efficacy and safety of VX-121/tezacaftor/deutivacaftor (VX-121/TEZ/D-IVA) in CF participants who are heterozygous for F508del and a minimal function

tezacaftor
fibrosis
forced expiratory volume
  • 0 views
  • 12 May, 2022
  • 81 locations
A Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Who Are Homozygous for F508del, Heterozygous for F508del and a Gating (F/G) or Residual Function (F/RF) Mutation, or Have At Least 1 Other Triple Combination Responsive (TCR) CFTR Mutation and No F508del Mutation

The purpose of this study is to evaluate the efficacy and safety of VX-121/tezacaftor/deutivacaftor (VX-121/TEZ/D-IVA) in CF participants who are homozygous for F508del, heterozygous for F508del

tezacaftor
fibrosis
cftr gene
forced expiratory volume
  • 4 views
  • 16 May, 2022
  • 95 locations
Impact of Discontinuing Chronic Therapies in People With Cystic Fibrosis on Highly Effective CFTR Modulator Therapy (SIMPLIFY)

Trikafta™. Trikafta (elexacaftor/tezacaftor/ivacaftor) is a combination CFTR modulator therapy that was approved by the Food and Drug Administration for people with CF who have at least one F508del

fibrosis
elexacaftor
ivacaftor
tezacaftor
forced expiratory volume
  • 65 views
  • 02 May, 2022
  • 78 locations
Impact of Rifabutin on the Pharmacokinetics of Elexacaftor/Tezacaftor/Ivacaftor

This is a prospective, single-center, fixed-sequence, nonrandomized, open-label study in healthy adults to investigate the impact of rifabutin on the pharmacokinetics of trikafta.

  • 0 views
  • 01 Oct, 2021
  • 1 location
Real World Clinical Outcomes With Novel Modulator Therapy Combinations in People With CF (RECOVER) (RECOVER)

RECOVER is a prospective, multicenter observational study designed to measure the real world clinical effectiveness of elexacaftor, tezacaftor and ivacaftor triple combination therapy (Kaftrio

spirometry
fibrosis
elexacaftor
ivacaftor
tezacaftor
  • 52 views
  • 18 May, 2022
  • 7 locations
Personalized Theratyping Trial

The purpose of this study is to explore the use of off-label CFTR modulators that may affect CFTR function in patients with CFTR mutations that are not currently approved for these drugs.

cftr modulators
  • 1 views
  • 01 Oct, 2021
  • 1 location
Testing Drug Efficacy in Cystic Fibrosis Through N-of-1 Trials (Nof1)

The purpose of this study is to validate and utilize a personalized medicine approach to identify potential treatments with current FDA approved CFTR modifiers for non-approved CF gene mutations. The study will perform ex vivo testing of CFTR function and current marketed CFTR modulating drugs on expanded nasal cells at …

  • 0 views
  • 18 May, 2022
  • 1 location
Trikafta in Cystic Fibrosis Patients

This clinical study will enroll 42 participants without the F508del mutation, carrying partial function or N1303K mutations not approved for Trikafta, and who are not expected to be approved for CFTR modulator treatment in the immediate future. Each participant will be given Trikafta for approximately four weeks. The study researchers …

ivacaftor
nasal potential difference
tezacaftor
pancreatic enzyme
neonatal screening
  • 8 views
  • 27 Apr, 2022
  • 3 locations
Home-Reported Outcomes in People With Cystic Fibrosis Taking Highly Effective CFTR Modulator Therapy

This is an observational cohort study, using data from Folia Health and the Cystic Fibrosis Foundation Patient Registry (CFFPR). Individuals taking elexacaftor/tezacaftor/ivacaftor (ETI) may be

tezacaftor
fibrosis
ivacaftor
elexacaftor
  • 0 views
  • 22 Sep, 2021
  • 1 location